Indications for plasma drug monitoring in patients with epilepsy. Implications for reducing costs

PharmacoEconomics

Volumn 11, Issue 4, 1997, Pages 343-349

  Eadie, Mervyn J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE; CARBAMAZEPINE; ETHOSUXIMIDE; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; REMACEMIDE; VALPROIC ACID; VIGABATRIN;

ANTICONVULSANT ACTIVITY; ATAXIA; CLINICAL FEATURE; COST CONTROL; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; EPILEPSY; HUMAN; HYPERSENSITIVITY REACTION; PRIORITY JOURNAL; REVIEW;

EID: 0030892319     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199711040-00005     Document Type: Review

References (32)

1. Schoenenberger RA, Tanasijevic MJ, Jha A, et al. Appropriateness of antiepileptic drug level monitoring. JAMA 1995; 274: 1622-6
2. Mattson RH. Antiepileptic drug monitoring: a reappraisal. Epilepsia 1995; 36 Suppl. 5: S22-9
3. Chadwick DW. Overuse of monitoring of blood concentrations of antiepileptic drugs. BMJ 1987; 294: 723-4
4. Beardsley RS, Freeman JM, Appel PA. Anticonvulsant serum levels are useful only if the physician appropriately uses them: an assessment of the impact of providing serum level data to physicians. Epilepsia 1983; 24: 330-5
5. Levy RH, Moreland TA. Rationale for monitoring free drug levels. Clin Pharmacokinet 1984: 9 Suppl. 1: 1-9
6. Levy RH, Schmidt D. Utility of free level monitoring of antiepileptic drugs. Epilepsia 1985; 26: 199-205
7. Macdonald RL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia 1993; 34 Suppl. 5: S1-8
8. Goldlust A, Su T-Z, Welty DF, et al. Effects of anticonvulsant drug gabapentin on the enzymes in metabolic pathways of glutamate and GABA. Epilepsy Res 1995; 22: 1-11
9. Messenheimer JA. Lamotrigine. Epilepsia 1995; 36 Suppl. 2: S87-94
10. Kilpatrick EK, Forrest G, Brodie MJ. Are lamotrigine concentrations clinically useful? A prospective study [abstract]. Epilepsia 1995; 36 Suppl. 3: S116
11. Naestoft J, Lund M, Larsen NE, et al. Assay and pharmacokinetics of clonazepam in humans. Acta Neurol Scand 1973; 49: 103-8
12. Chadwick DW. Concentration-effect relationship of valproic acid. Clin Pharmacokinet 1985; 10: 155-63
13. Ben-Menachem E. Vigabatrin. Epilepsia 1985; 36 Suppl. 2: S95-104
14. Haegele KD, Schecter PJ. Kinetics of the enantiomers of vigabatrin afler an oral dose of the racemate or the active S-enantiomer. Clin Pharmacol Ther 1986; 40: 581-6
15. Rey E, Pons G, Olive G. Vigabatrin: clinical pharmacokinetics. Clin Pharmacokinet 1992; 23: 267-78
16. Gram L, Lyon BB, Dam M. Gamma-vinyl-GABA: a single-blind trial in patients with epilepsy. Acta Neurol Scand 1983; 68: 34-9
17. Gram L, Klosterskov P, Dam M. γ-Vinyl-GABA: a double-blind placebo-controlled trial in partial epilepsy. Ann Neurol 1985; 17: 262-6
18. Faigle JW, Feldmann KF. Carbamazepine: chemistry and biotransformation. In: Levy RH, Mattson RH, Meldrum BH, editors. Antiepileptic drugs. 4th ed. New York: Raven, 1995: 499-513
19. Baumel IP, Gallagher BB, Mattson RH. Phenylethylmalonamide: an important metabolite of primidone. Arch Neurol 1972; 27: 34-41
20. Butler TC, Waddell WJ. Metabolic conversion of primidone (Mysoline) to phenobarbital. Proc Soc Exp Biol Med 1956; 93: 544-6
21. Baillie TA, Sheffels PR. Valproic acid: chemistry and biotransformution. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven, 1995: 589-604
22. McKauge L, Tyrer JH, Eadie MJ. Factors influencing simultaneous concentrations of carbamazepine and its epoxide in plasma. Ther Drug Monit 1981; 3: 63-70
23. Brodie MJ, Forrest G, Rapeport WG. Carbamazepine-10, 11-epoxide concentrations in epileptics on carbamazepine alone and in combination with other anticonvulsants. Br J Clin Pharmacol 1983; 16: 747-9
24. Gowers WR. Epilepsy and other chronic convulsive disorders. London: J & A Churchill, 1881
25. Elwes RD, Johnson AJ, Shorvon SD, et al. The prognosis for seizure control in newly diagnosed epilepsy. N Engl J Med 1984; 311: 944-7
26. Reynolds EH. The prevention of chronic epilepsy. Epilepsia 1988; 29 Suppl. 1: S25-8
27. Camfield C, Camfield P, Gordon K, et al. Does the number of seizures before treatment influence ease of control or remission of childhood epilepsy? Not if the number is 10 or less. Neurology 1996; 46: 41-4
28. Shorvon S. Is there a therapeutic range for phenytoin? In: Dam M, Richens A, editors. Fifty years of phenytoin. London: Royal Society of Medicine Services, 1987: 13-7
29. Turnbull DM, Rawlins MD, Weightman D, et al. 'Therapeutic' serum concentration of phenytoin: the influence of seizure type. J Neurol Neurosurg Psychiatry 1984; 47: 231-4
30. Schmidt D, Einicke I, Haenel F. The influence of seizure type on the efficacy of plasma concentrations of phenytoin, phenobarbital, and carbamazepine. Arch Neurol 1986; 43: 263-5
31. Woo E, Chan YL, Chan YW, et al. If a well-stabilized epileptic patienl has a subtherapeutic antiepileptic drug level, should the dose be increased? A randomized prospective study. Epilepsia 1988; 29: 129-39
32. Livingstone S, Berman W, Pauli LL. Anticonvulsant blood drug levels: practical applications based on 12 years experience. JAMA 1975; 232: 60-2